On June 25, Lee Dong-geon, a researcher at Shinhan Financial Investment, stated, "A large-scale license agreement worth 4.7 trillion KRW was signed with a global top 10 pharmaceutical company. This contract covers a total of six targets, with a structure to receive up to 776.3 billion KRW in milestones and royalties per target. Attention is drawn to the scalability of the company that signed the largest platform license agreement in Korea. In other words, the commercialization potential is higher compared to new drugs, and since only clinical phases 1 and 3 are conducted, the required time is significantly shorter." He set Alteogen’s target price at 340,000 KRW.
Over the past five days, individual investors have net purchased 48,800 shares of Alteogen, while foreigners and institutions have net sold 5,779 shares and 28,477 shares, respectively.

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

